We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

Then his mother, Alia Hayes, got some bad news. The manufacturer, GSK, was going to stop manufacturing the brand-name ...

GSK GSK1.94%increase; green up pointing triangle cut its full-year vaccine sales outlook after key shots for respiratory ...

The biggest vaccine brand it has acquired in the deal is Bexsero, a new vaccine to prevent meningitis B, with a further candidate vaccine in late-stage development, MenABCWY. GSK intends to report ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug. GSK suffered ...

GSK is currently the market leader in the meningococcal vaccine market, racking up sales of £1.26 billion (almost $1.6 billion) last year across the Bexsero and Menveo brands, but is having to ...

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billi | GSK has stopped development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 ...

Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...

Lenacapavir first hit the market in 2022 under the brand name Sunlenca for use alongside other agents in patients with multidrug-resistant HIV. While GSK was first to introduce a long-acting PrEP ...